Dbv Technologies S.A. DBVT
We take great care to ensure that the data presented and summarized in this overview for DBV Technologies S.A. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DBVT
View allLatest Institutional Activity in DBVT
Top Purchases
Top Sells
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
Insider Transactions at DBVT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
565
-0.51%
|
$0
$0.57 P/Share
|
|
Nov 22
2024
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
342
-0.31%
|
$0
$0.53 P/Share
|
|
Nov 21
2024
|
Virginie Boucinha Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+33.33%
|
-
|
|
Nov 21
2024
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,350
-2.05%
|
$0
$0.54 P/Share
|
|
Nov 21
2024
|
Pharis Mohideen Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+23.43%
|
-
|
|
Jul 29
2024
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,785
-2.2%
|
$0
$0.98 P/Share
|
|
May 24
2024
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
660
-0.81%
|
$660
$1.36 P/Share
|
|
May 22
2024
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
382
-0.46%
|
$382
$1.38 P/Share
|
|
Mar 08
2024
|
Daniel Tasse CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Direct |
17,094
+50.0%
|
$0
$0.83 P/Share
|
|
Feb 06
2024
|
Adora Ndu |
BUY
Open market or private purchase
|
Direct |
1,825
+50.0%
|
$0
$0.89 P/Share
|
|
Nov 22
2023
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,245
-2.66%
|
$2,245
$1.74 P/Share
|
|
Nov 20
2023
|
Virginie Boucinha Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+50.0%
|
-
|
|
Nov 20
2023
|
Pharis Mohideen Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+29.3%
|
-
|
|
Aug 25
2023
|
Timothy E Morris Director |
BUY
Open market or private purchase
|
Direct |
12,000
+50.0%
|
$12,000
$1.52 P/Share
|
|
Aug 01
2023
|
Daniel B Soland Director |
BUY
Open market or private purchase
|
Direct |
15,000
+42.86%
|
$15,000
$1.62 P/Share
|
|
May 24
2023
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
469
-0.94%
|
$1,407
$3.54 P/Share
|
|
Nov 24
2022
|
Pharis Mohideen Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,792
-3.47%
|
$3,584
$2.88 P/Share
|
|
Nov 21
2022
|
Sebastien Robitaille Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,000
+17.98%
|
-
|
|
Nov 21
2022
|
Pharis Mohideen Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,500
+25.29%
|
-
|
|
Jul 29
2022
|
Pharis Mohideen Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+22.62%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 18.9K shares |
|---|---|
| Grant, award, or other acquisition | 54K shares |
| Open market or private sale | 6.08K shares |
|---|